Deutsche Bank analyst George Hill lowered the firm’s price target on Hims & Hers to $31 from $42 and keeps a Hold rating on the shares. The firm notes that the company is “under siege” following the reversal of its GLP-1 pill launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Canaccord cuts Hims & Hers target, says legal risk may be priced in
- Prudent Pause, Strong Potential: Why Hims & Hers Remains a Buy Amid GLP‑1 Regulatory Scrutiny
- ‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts
- Hims & Hers falls -23.2%
- Midday Fly By: Transocean to buy Valaris, Kyndryl sinks after CFO exit